These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 32479195)

  • 21. Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk: Where Do We Stand?
    Lloyd-Jones DM
    JAMA Cardiol; 2017 Sep; 2(9):937-938. PubMed ID: 28768306
    [No Abstract]   [Full Text] [Related]  

  • 22. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
    Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP;
    J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia.
    Khan SA; Naz A; Qamar Masood M; Shah R
    Am J Cardiol; 2020 Nov; 134():69-73. PubMed ID: 32892993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia.
    Reijman MD; Schweizer A; Peterson ALH; Bruckert E; Stratz C; Defesche JC; Hegele RA; Wiegman A
    Eur J Prev Cardiol; 2022 Jul; 29(9):1361-1368. PubMed ID: 35175352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Familial hypercholesterolemia: Detect, treat, and ask about family.
    Shah NP; Ahmed HM; Wilson Tang WH
    Cleve Clin J Med; 2020 Feb; 87(2):109-120. PubMed ID: 32015064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
    Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP
    Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
    Santos RD; Ruzza A; Hovingh GK; Wiegman A; Mach F; Kurtz CE; Hamer A; Bridges I; Bartuli A; Bergeron J; Szamosi T; Santra S; Stefanutti C; Descamps OS; Greber-Platzer S; Luirink I; Kastelein JJP; Gaudet D;
    N Engl J Med; 2020 Oct; 383(14):1317-1327. PubMed ID: 32865373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis.
    Matta A; Bongard V; Bouisset F; Taraszkiewicz D; Rabès JP; Ferrières J
    Med Sci Monit; 2021 May; 27():e928784. PubMed ID: 33958572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular aspects of hypercholesterolemia treatment: current perspectives and hopes.
    Ahangari N; Ghayour Mobarhan M; Sahebkar A; Pasdar A
    Ann Med; 2018 Jun; 50(4):303-311. PubMed ID: 29578362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Long-lasting LDL-C lowering: silence at last].
    Achard M; Buhayer A; Dobretz K; Ehret G; Mach F
    Rev Med Suisse; 2021 May; 17(740):1039-1046. PubMed ID: 34042340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First case report of familial hypercholesterolemia in an Omani family due to novel mutation in the low-density lipoprotein receptor gene.
    Al-Hinai AT; Al-Abri A; Al-Dhuhli H; Al-Waili K; Al-Sabti H; Al-Yaarubi S; Al-Hashmi K; Banerjee Y; Al-Zakwani I; Al-Rasadi K
    Angiology; 2013 May; 64(4):287-92. PubMed ID: 23162007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.
    Stein EA; Honarpour N; Wasserman SM; Xu F; Scott R; Raal FJ
    Circulation; 2013 Nov; 128(19):2113-20. PubMed ID: 24014831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Familial Hypercholesterolemia: Although Identification Advances, Appreciation and Treatment Lag.
    Baum SJ; Brown AS
    Rev Cardiovasc Med; 2018; 19(S1):S25-S30. PubMed ID: 30207555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1.
    Landmesser U; Haghikia A; Leiter LA; Wright RS; Kallend D; Wijngaard P; Stoekenbroek R; Kastelein JJ; Ray KK
    Cardiovasc Res; 2021 Jan; 117(1):284-291. PubMed ID: 32243492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inclisiran, the billion-dollar drug, to lower LDL cholesterol - is it worth it?
    Doggrell SA
    Expert Opin Pharmacother; 2020 Nov; 21(16):1971-1974. PubMed ID: 32749892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subclinical coronary atherosclerosis and cardiovascular risk stratification in heterozygous familial hypercholesterolemia patients undergoing statin treatment.
    Miname MH; Bittencourt MS; Nasir K; Santos RD
    Curr Opin Lipidol; 2019 Apr; 30(2):82-87. PubMed ID: 30649025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
    Della Badia LA; Elshourbagy NA; Mousa SA
    Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.
    Ray KK; Troquay RPT; Visseren FLJ; Leiter LA; Scott Wright R; Vikarunnessa S; Talloczy Z; Zang X; Maheux P; Lesogor A; Landmesser U
    Lancet Diabetes Endocrinol; 2023 Feb; 11(2):109-119. PubMed ID: 36620965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment].
    Češka R; Štulc T; Votavová L; Schwarzová L; Vaclová M; Freiberger T
    Vnitr Lek; 2016; 62(11):887-894. PubMed ID: 28128575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inclisiran-New hope in the management of lipid disorders?
    Dyrbuś K; Gąsior M; Penson P; Ray KK; Banach M
    J Clin Lipidol; 2020; 14(1):16-27. PubMed ID: 31879073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.